ʻO Galvus Met - nā ʻōlelo aʻoaʻo piha no ka hoʻohana ʻana, nā loiloi o ka maʻi maʻi a me nā kauka

ʻO Galvus Honey kahi lāʻau lapaʻau hoʻohui hoʻohui me ka mana o ka lāʻau lapaʻau hypoglycemic. Ua kūkulu ʻia ia e hana i ka glycemia i ka maʻi maʻi maʻi me ka maʻi maʻi lua. Ka mana ikaika i ka lāʻau lapaʻau i ka hana kaohi o ka insulin a me ka glucagon.

Manaʻo ka European Medical Association e ʻoi aku ka maikaʻi o Galvus Honey i ʻoi aku ka maikaʻi ma mua o kona mea i hoʻokumu mua ʻia, ʻo Galvus, ua ʻōlelo ʻia e hoʻohana wale nō no ka intolerance pilikino i metformin.

ʻO ka wehewehe ʻana i ke ʻano dosis

I loko o ka pūnaewele olakino, hāʻawi ʻia ka lāʻau lapaʻau i loko o ke ʻano o nā papa pālahalaha; e loaʻa ana i kēlā me kēia me ʻelua o nā mea hoʻoikaika: 50 mg o vildagliptin a me 500, 850 a i ʻole 1000 mg o metformin. Hoʻohana ʻia ka Magnesium stearate, hyprolose, hypromellose, talc, titanium dioxide, macrogol 4000 a me ka mea hoʻoneʻe hao ʻoi ka mea hoʻohana.

Aia i kēlā me kēia kime 10 mau papa. Hoʻopili ʻia nā papa i nā pahu o 3 mau ʻāpana, ua loaʻa iā ia kēlā me kēia pākele he Galvus Met.

• 50/500 mg - nā papa oval me nā kihi ʻihi loa i ka pena o kahi hue-melemele. Hoʻopili ʻia ʻo LLO ma kekahi ʻaoʻao a ʻo NVR i kahi kua.
• 50/850 mg - kahi pānaʻi like papa, ʻo ia wale nō ka melemele-hina a kūpono nā māka: SEH ma ka lima hoʻokahi a me NVR ma ka ʻaoʻao.
• 50/1000 mg - nā papa i ʻokoʻa i ka ʻano i kau ʻia ma kahi pale i kahi saturated o ka melemone me ka hoʻohui o nā hina a me nā puʻupuʻu: NVR - ma ka ʻaoʻao mua a me FLO - ma ke kua.

Hiki i nā pono Pharmacological

Loaʻa ka hypoglycemic potoma o ka lāʻau lapaʻau e ʻelua mau ʻano o nā mea maʻamau, kēlā me kēia mea i hana pono ai i ke ʻano. ʻO kā lākou mau mea paʻakikī e hiki iā ʻoe ke mālama pono i ka glycemia i ka lā.

1. ʻO Vildagliptin - kahi hoʻomehana o dipeptidyl peptidase-4 (DPP-4) - hoʻonui i ka naʻau o nā ʻoli i ka insulin, hoʻonui i kona hana. Hāʻawi ʻia kēia hopena ma o ka hoʻoulu ʻia e nā ʻano o ka glyptin o ka hana o ka protein e pono ai no ka pancreas - ke ʻano peptide like-glucagon like 1 (GLP-1) a me ka glucose-dependantine insulin -ropyp polypeptide (HIP).
2. ʻO Metformin, ka pūhui o ka hui biguanide hydrochloride, e hoʻohālikelike i nā hanana glycemic ma o ka hoʻemi ʻana o ka helu o nā haʻalulu o nā powa i loko o ka ʻōpū liʻiliʻi, e hoʻemi ana i ka hana o ka glycogen i ka ate a hoʻonui i ka hoʻohana ʻana i nā ʻōhua peripheral. Hiki i ka pūhui ke hoʻoulu i ka hypoglycemia.

Me ka hoʻohana waha ʻana o ka lāʻau, vildagliptin a me ka metformin e komo i ka kahe koko ma o ka paia o ka ʻōpū, hiki i ka hopena therapeutic i nā minuke 25-30 a hoʻāliʻi malū ʻia i nā ʻāpana a me nā kiko. ʻO nā kaʻina metabolic o ka metabolite o Galvus Met ka mea i kaʻeha i ka pehu. E hoʻolei i nā huahana hoʻōla i nā pōpoki me nā urine. Hōʻike ʻia ka manawa manawa no ka hapalua o kēia mauʻano maʻamau ma kahi o ʻekolu hola.

I ka wā o nā maʻi paʻakikī me nā lāʻau lapaʻau ʻelua i kēlā me kēia lā o ka metformin 1500-3000 mg a me vildagliptin 50 mg, ua hōʻiliʻili ʻia ma luna o 2 mau noi, kahi nui o ke kahe koko i hoʻopaʻa ʻia ma kahi o hoʻokahi makahiki. I ka manawa like, nā haʻahaʻa glycosylated hemoglobin i hoʻemi ʻia e 0.7%, i ka manawa i hoʻohālikelike ʻia me ka hui mana, ka mea i loaʻa i nā metformin wale nō.

I ka maʻi maʻi maʻi e pili ana i ka mālama nui o Galvus Metom, ʻaʻole i hōʻike nui ʻia ka hoʻoponopono koʻikoʻi. Ma luna o 24 mau pule o ka lāʻau lapaʻau, ua hōʻike ʻia kahi emi nui i ke kahe o ke koko i nā mea maʻi hypertensive me ka maʻi diabetes 2 type. Nā helu Hypoglycemic helu helu helu liʻiliʻi.

I ka manawa i kauoha ʻia ai ʻo Galvus Meta i ka wā o ka mālama ʻana me ka insulin (ma kahi o nā papa o 41) i nā poʻe maʻi maʻi maʻi e komo nei i ka hoʻopaʻa ʻana, ua hāʻule ka nui o ka hemoglobin glycosylated e 0.72% ʻAʻole like ka hypoglycemia ma ka subgroup hoʻokolohua a ma ka hui placebo ʻaʻole i ʻokoʻa ke alapine o nā hihia.

Me ka hoʻohana pākuʻina o glimepiride (mai ka 4 mg / lā) me Galvus Met, kahi hōʻemi nui loa i ka hemoglobin glycosylated i hōʻike pū ʻia - e 0.76%.

Nā hiʻohiʻona o nā pharmacokinetics

Vildagliptin

Inā ʻoe e lawe i nā papa ma mua o ka papaʻaina, hoʻāla koke ka mea kanu a me ka hōʻea ma hope o kona mau minuke 105 ma hope o ke kau ʻana. Ke hoʻohana ʻia i ka lāʻau lapaʻau me ka meaʻai, hoʻemi iki ka hapa o ka hoʻopili ʻana.

ʻO ka bioavailability kūʻokoʻa loa e pili ana i ka lāʻau - 85%. ʻO ka laweʻana o ka metabolite ma waena o ka plasma a me ka erythrocytes e kūleʻa, e nāwaliwali ana i ka ʻōmole o ke koko - he 9,3% wale nō.

ʻO ke ala nui o ka hōʻemi ʻana i ka lāʻau ma ka biotransformation, ʻo 69% o ka nui i loko o ke kino e hoʻohuli ai i ka metabolite LAY151 pharmacologically inactive. Ke hele nei o nā vildagliptin ma o nā keiki (85%) a me nā ʻāpana (23%).

ʻO nā ʻelele o nā hui ʻano ʻē, kāne kāne paha, nā ʻano paona like ʻole ke hōʻike nei i like me nā pharmacokinetics like ʻole o ka lāʻau.

Me ka emiʻole hepatic i ke ʻano maʻalahi a maʻalahi paha, e hāʻule ana ka bioavailability o vildagliptin i 20%, i loko o ka ulu koʻikoʻi, e piʻi ana ka 22%.

Me nā pathology renal, ʻano maʻalahi, maʻalahi a me ke ʻano paʻakikī o ka AUC, ʻo ka vildagliptin e ulu i 1,4 a 2 mau manawa.

ʻO nā hopena o ka vildagliptin ma luna o ka pharmacokinetics o nā keiki i aʻo ʻole ʻia.

Metformin

I kahi papa o 500 mg, ʻo ka bioavailability o ka metformin he 50-60% inā lawe ʻia ma mua o ka papa ʻaina. Me ka hoʻonui nui o ka dosage, hoʻonui ka hoʻonui ʻana i ka proportionally. Inā lawe ʻoe i ka lāʻau lapaʻau i ka ʻokoʻa me ka meaʻai, no ka emi ʻana o bioavailability.

Me kahi pākahi hoʻokahi, ʻaʻole i hoʻopaʻa nā metabolite i ka protein plasma (no ka hoʻohālikelike ʻana, pae ʻaila sulfonylurea e hoʻopaʻa pū ai i 90%). Me ka hoʻohana mau ʻana, komo ka lāʻau i loko o nā ʻāpana koko ʻulaʻula.

Ua hōʻike ʻia nā kaha intravenous kaha i ka lāʻau lapaʻau i nā mea hoʻōla ikaika e hōʻike ai i ka hana maʻamau o ka maʻi ma ka like pū. ʻAʻole i loaʻa ka metabolites ma loko o ke ake. I ka maʻi maʻi, a ʻo 90% o nā lāʻau lapaʻau i lawe ʻia e nā keiki i loko o 24 mau hola.

ʻAʻole pili ka hopena i ka moekolohe i ka pharmacokinetics o ka lāʻau. Na ke maʻi ʻaʻai o nā ʻōiwi ʻē aʻe i hoʻopaʻa pono i ka like no ka metformin.

ʻAʻole hōʻike ʻia nā hiʻohiʻona o ka hilo ʻana, ka lawe ʻana a me ka wehe ʻana o ka lāʻau i nā mea maʻi me nā pathologies ate. Me nā pathology renal, hoʻonui ʻia ka hapalua-ola. Ma muli o ka emi ʻana o ke kaupaona o ka maʻi i nā maʻi maʻi, ʻike ʻia nā hopena like. ʻAʻohe ʻikepili i ka hopena o ka lāʻau lapaʻau ma nā hopena hopena i nā keiki.

I hōʻike ʻia no ka lāʻau lapaʻau

Hoʻolālā ʻia ka hui ʻana e mālama i ka maʻi maʻi maʻi me ka maʻi diabetes type 2. Hoʻokumu ʻia ma Galvus Meta, loaʻa nā ʻano regimens therapeutic.

1. Monotherapy - e hoʻomaʻamaʻa i nā gula, hoʻohana lākou i hoʻokahi lāʻau lapaʻau - Galvus Met.
2. Ka hoʻokaʻawale ʻana i nā mea ikaika o Metformin a me Vildagliptin e like me nā lāʻau kūʻokoʻa.
3. Hoʻohui hui pūʻā i nā pakanā me nā derivatives o sulfanylurea.
4. Hoʻololi i ka hoʻolālā kiʻi pū me ka hoʻohui o insulin i Galvus Meta.
5. Ma ke ʻano he lāʻau lapaʻau mua i hoʻohana ʻia ma ka hoʻomaka ʻana o ka lāʻau lapaʻau, i ka wā e ʻai ai ka meaʻai a me ka haʻalulu haʻalulu haʻahaʻa, ʻaʻole i alakaʻi i ka hopena e makemake ai.

ʻO Galvus metome lapaʻau no ka wahine hāpai a me ka lactating

ʻO nā hoʻokolohua ma nā holoholona hānai, i hāʻawi ʻia he dosis o vildagliptin he 200 mau manawa i ʻoi aku ma mua o ka mea maʻamau, ka mea i hōʻike ʻole ʻia ai ka lāʻau lapaʻau i ka hoʻomohala ʻana o nā keiki a ʻaʻohe i ka hopena teratogenic. ʻO ka hoʻohana ʻana o Galvus Meta i loko o kahi waihona o 1/10 e hōʻike ana i kahi hopena like.

ʻAʻole lawa ke aʻo ʻia ka hopena o ka lāʻau i loko o ke kanaka. No laila, ʻaʻole i kuhikuhi ʻia nā wāhine hāpai. Hoʻomoʻe ka metformin i ka waiū umauma, ʻaʻohe ʻikepili ma ka komo ʻana o ka vildagliptin.

I ka holoʻokoʻa, ʻaʻole i hoʻohana ʻia ʻo Galvus Met no ka hoʻoulu wahine.

Ka mea a contogicated ʻo ia ka hypoglycemic agent

Nā alaala i kuhikuhi ʻole ʻia ka metabolite:

• ʻO ka make pilikino pilikino, hypersensitivity i kekahi o nā mea o ka lāʻau lapaʻau;
• ʻO ka maʻi diabetes type 1 - me kahi maʻi e hilinaʻi nei i ka insulin i kēia ʻano, pono ʻia ka insulin;
• I kekahi mau lā ma mua o ka hana, X-ray a me radioisotropic hoʻokolokolo, invasive diagnosis;
• ʻO ka Acetonemia kahi maʻi metabola i hiʻohiʻona i ka hiʻohiʻona o nā kino ketone i nā wai o nā ola, no ka mea i loaʻa ka hyperglycemia;
• Nā ʻōhua Renal (ma ka hana a i ʻole ke ʻano o ke ʻano), nā kaʻina e hoʻonāukiuki i ka hoʻomehana - kahi hana hōʻiliʻili nui o ke kino ma ke ʻano o ka maʻi ʻana a i ʻole pinepine ka hele ʻana, ka ʻeha, ka maʻi (sepsis, nā maʻi ʻōpū o ka hanu);
• ʻO ka hapa o ka puʻuwai e pili ana i nā kūlana e hōʻemi ana i kāna hana (cirrhosis, hepatitis);
• ʻO ka maʻi Cardiovascular, puʻuwai puʻuwai, pōkole o ka hanu;
• Alcoholism ma ke ʻano he maʻi a i ʻole ka palaka ʻawaʻawa;
• ʻO kaʻai hypypororic, i ka manawa a 1000 kcal / lā komo i ke kino ;;
• ʻO kēlā me kēia wā o ka hāpai a me ka lactation;
• Nā keiki - ʻaʻole i hoʻokumu ʻia ka palekana a me ka hopena o ka lāʻau lapaʻau.

Pehea e hoʻopili ai i ka lāʻau lapaʻau

E hoʻopau ʻia ka papa papaʻu i kona ʻano holoʻokoʻa, me ka ʻole o ka huki ʻana a i ʻole hoʻolā ʻia, holoi ʻia me ka nui o ka wai i ka wai mehana. Inā ʻoe e lawe i ka paila me ka meaʻai, ua hoʻemi ʻia ka nui o nā ʻaoʻao.

ʻO ka make o Galvus Meta hilinaʻi i ka kiʻekiʻe o ka uku o ke kō, nā hopena o ka hoʻomaʻamaʻa mua me nā analogue, a me ka lōʻihi o ka maʻi. I kekahi hihia, he kauka ke lapaʻau lāʻau.

Inā koho ʻia ka lāʻau lapaʻau no ka manawa mua, me ka hoʻohui i kahi mea kīnā ʻole pono a me ka hana kino, ʻo kona ʻano o ka 50/500 mg (ʻo ka vildagliptin mua, ʻo ka lua ka metformin). I ka wā e hiki mai ana, me ka loaʻa ʻole o ka hopena therapeutic, ka mea i hoʻoholo ʻia e nā keʻena hana noiʻi, hiki ke hoʻoponopono ʻia ke kao.

Ke ʻike mua nei ka mea maʻi i nā lāʻau lapaʻau (ua lawe ʻē ʻia ʻo ia iā lākou a i ʻole nā ​​mea hoʻohui ʻē aʻe), ʻoluʻolu lākou i kekahi o nā koho - 50/850 mg a i ʻole 50/1000 mg.

I nā makahiki ʻelemakule a i ʻole me ka hoʻomohala ʻana i nā ʻōkuhi kiki, nānā pinepine ʻia ka nui o ka nui.

No ka loiloi i ka hopena o ka loaʻa ʻana o Galvus Metom, pono ia e nānā i ke kiʻekiʻe o ka honi (ma ka home, me kahi glucometer, a ma ka pūnaehana maʻamau) maʻamau.

Nā hopena hopena

ʻAʻole kākau ʻia nā hopena he hiki ʻole, akā pono ia e aʻo i ka papa inoa ma mua o ka hoʻokomo ʻana i ka maʻi maʻi.

1. ʻO ka maʻi Gastrointestinal - maʻi dyspeptic, puʻuwai, pancreatitis, ʻona ʻona i loko o ka waha, ka hoʻopihapiha ʻole o nā huaora B12.
2. CNS - ka nalowale o ka hoʻomohala ʻana, ke poʻo, ka lulu lima.
3. Nā huhui naʻau a me nā hua bile - ka maʻi hepatitis a me nā lehelehe o ke ake.
4. ʻŌnaehana musculoskeletal - ʻāwili a me ka ʻehaʻeha o ka naʻau.
5. Paʻa - blisters, swelling, ʻili maloʻo.
6. Metabolism - ka lactic acidosis (hoʻonui i ka hoʻomohala ʻana i ka waikik uric, pane kūkaʻi o ke kaiapuni).
7. ʻAiuma - rashes i ke kino, kaʻili, urticaria; i loko o nā hopena koʻikoʻi - ka edema angioedema Quincke (ke kīwaha o ka maka a me ka ʻōiwi) a me ka pīhoihoi anaphylactic (kahi kīwī i ke kahaha o ke koko, i hoʻohui ʻia e ka nui o ka hoʻoluhi kino).

   
   

ʻO kekahi manawa ulu ka hypoglycemia me nā umauma o ka palu maloʻo, nā lima haʻalulu. I nā ʻōmaʻomaʻi mua, pono ʻoe e inu i ka hapalua o ke kīʻaha kīʻaha a i ʻole waiʻaʻai, ʻai ʻaina.

Nā ʻōlelo kikoʻī

I ke kohoʻana i kahi lāʻau lapaʻau, pono ke maʻi maʻi maʻi e aʻo pono iā ia iho. E kōkua nā ʻōlelo kūikawā e pale i nā hopena ʻaoʻao.

• ʻAʻole Galvus Met kahi analogue o ka insulin, he mea nui loa, ma mua o nā mea āpau, no ka maʻi maʻi me ka diabetes.
• I ka mea me ka lāʻau lapaʻau, mālama pono ʻia ka mālama ʻana i nā puna koko (ʻelua a ʻoihana a me ka mea kū hoʻokahi, e hoʻohana ana i kahi glucometer).
• ʻO kēlā me kēia mahina, loiloi nā hana ʻenehana i ke ʻano o nā pūpū, nā ate, a me ka hoʻohuihui o ka waikawa lactic.
• I ka wā mālama, ʻaʻole hiki i ke ʻāpono ʻo Galvus Metom ke inu i ka waiʻona - hiki ke kōkua i kēia mea i ka hoʻomohala ʻana o ka acidact lactic.
• ʻO ka hōʻemi ʻana o ka huaora B12, i hōʻemi ʻia e ka hoʻohana ʻana i kahi lāʻau lapaʻau, hiki ke hoʻonāukiuki i ka anemia a me ka neuropathy.
• ʻO nā keiki, hānau a me nā māmā lactating ʻo Galvus Met i hōʻole ʻia.
• Hoʻopili nā mea ikaika o ka metabolite me nā lāʻau lapaʻau he nui, i ka wā e kahakiʻi ai i kahi hoʻoponopono lapaʻau, pono e ʻike ʻia ke kauka e pili ana i nā lāʻau lapaʻau a pau.
• ʻAʻole i aʻo ʻia ka hopena o Galvus Meta i ka hopena psychomotor a me ke kiʻekiʻe o ke neʻe ʻana o ka makaʻala. I ka manawa e hana pū ai me nā mīkini a me nā ʻenekena i ka wā o ka mālama ʻana me ka lāʻau lapaʻau, pono pono e kiaʻi nui kekahi.

Ke keu

Inā ʻoi aku ka nui o nā pānana i ʻōlelo ʻia i nā manawa he nui, hoʻomohala ʻia ka myalgia, hypoglycemia, dyspeptic disorders, ka huehue o nā poʻo o ka lactic acidosis (mai kahi nui o ka metformin) i hoʻomohala. ʻO nā hōʻailona o kahi overdose e nalowale ma hope o ka hoʻokuʻu ʻana o ka mālama ʻana.

Me kēlā mau ʻōuli, hoʻopau ʻia ka lāʻau lapaʻau, holoi ʻia me ka papa gastrointestinal a me ka mālama ʻana i ka hōʻailona maʻi. Ke hoʻohana nei i ka hemodialysis, hiki ke hoʻopiha piha wale ʻia ka metformin, ua hoʻopili ʻia ka vildagliptin.

ʻO Galvus Met - kahi kikoʻī

Inā mākou e hoʻohālikelike i ka haku mele a me nā hopena o ka mālama ʻana, a laila e like me nā mea ikaika a me ka effapeutic efficacy, hiki i nā analogues ke:

• Nova Met;
• Sofamet;
• Trazenta;
• Methadiene;
• ʻIvalelo Plin.

Ke waiho nei i nā hōʻike ʻana a me ke kumu kūʻai o ka lāʻau lapaʻau

Wahi a nā ʻōlelo kuhikuhi, e kūpono ke hoʻohana ʻana o Galvus Met i loko o 18 mau mahina mai ka lā o ka hoʻokuʻu ʻana, e pili ana i ka mālama pono. Pono e hoʻokaʻawale ʻia nā lāʻau lapaʻau. He wahi ʻeleʻele a maloʻo ʻole i hiki ke nānā ʻia i ka nānā ʻana o nā keiki e kūpono no ka mālama ʻana, me nā kūlana wela a hiki i 30 ° C.

Hoʻokuʻu ʻia kahi lāʻau lapaʻau. No Galvus Met, ua hoʻoholo ʻia ke kaʻi ʻana ma ke ʻano:

1. 50/500 mg - kahi awelika o 1457 rubles;
2. 50/850 mg - kahi awelika o 1469 rubles;
3. 50/1000 mg - kahi awelika o 1465 rubles.

ʻOiai me ka hoʻohana pono ʻana i kēlā me kēia lā, ʻaʻole pau ka maʻi maʻi maʻi āpau me kēia kumukūʻai, ʻo ka hapa nui o nā hoʻopiʻi a pau mai nā penikala me nā uku liʻiliʻi. Eia nō naʻe, ʻokoʻa mau nā huahana o ka hui ʻo Swiss Novartis Pharma e ko lākou ʻano impeccable, ʻaʻole ia mea i loko o ka waihona kālā o nā mākeke hypoglycemic.

ʻO Galvus Met - nā manaʻo kūkā o nā maʻi maʻi a me nā kauka

Ma nā papa kūkala, he pane maikaʻi nā endocrinologists i nā hopena o ka hoʻomaʻamaʻa ʻana o Galvus Metom. ʻAʻole ia e kuhikuhi i kuhikuhi i nā pilikia oncological, ʻoiai ʻo DPP-4, he enzyme e kālai ana i ka hoʻomohala ʻana o nā neoplasms, ua kālai ʻia e Galvus Metom. I ka maʻi maʻi pancreatic, maʻa pinepine ke ʻano o ka insulin. Ua hui ʻia nā loiloi e pili ana i nā maʻi maʻi e pili ana iā Galvus Mete, ʻo ke kumu nui o ka hoʻopaʻapaʻa ʻana he ʻano kumukūʻai.

Hōʻike ka ʻike e pili ana i ka lāʻau lapaʻau Galvus Met i nā hopena hypoglycemic hoʻopili i ka insulin a me ka glycogen ma ke kino no nā ʻōkuhi maʻamau, akā ua hoʻolako ʻia no nā kumu ʻike a ʻaʻole hiki ke lilo i kumu alakaʻi no ka maʻi a i ʻole ka lāʻau lapaʻau ponoʻī.